|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02427 GUANZE MEDICAL
Nominal 
0.380 -0.070 (-15.556%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 156,072 | -11.879% | 177,112 | 211,076 | 184,435 | 140,825 |
| Cost of Sales | (70,667) | -26.493% | (96,136) | (135,377) | (122,860) | (94,410) |
| Gross Profit | 85,405 | 5.470% | 80,976 | 75,699 | 61,575 | 46,415 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 38,650 | 28.997% | 29,962 | 33,057 | 39,003 | 29,595 | |
| Taxation | (10,728) | -8.119% | (11,676) | (9,989) | (9,960) | (7,271) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (355) | 3.801% | (342) | (133) | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 27,567 | 53.628% | 17,944 | 22,935 | 29,043 | 22,324 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 18 | -98.198% | 999 | 556 | 761 | (35) |
| Depreciation & Amortisation | 6,007 | 13.554% | 5,290 | 4,418 | 3,287 | 2,068 |
| Directors' Emoluments | 2,080 | 564.537% | 313 | 234 | 198 | 272 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 3.000 | 50.000% | 2.000 | 3.000 | -- | -- |
| DPS (cts) | 1.903 | -- | 1.840 | -- | -- | -- |
| Dividend Payout Ratio (%) | 63.440% | -- | 91.992% | -- | -- | -- |
| Cash flow per share ($) | 0.009 | -- | 0.012 | 0.004 | -- | -- |
| NBV per share ($) | 0.284 | -- | 0.274 | -- | -- | -- |
| Remarks: | Real time quote last updated: 28/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -160,000 |
| %Change | -- |
| EPS / (LPS) | RMB -0.000 |
| NBV Per Share (¥) | RMB 0.254 |